Open company graph database — free web & API
Login

KaioM BioScience Co., Ltd.

株式会社カイオム・バイオサイエンスChiome Bioscience Inc.AliasChiome BioscienceAlias
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
63
Related companies
13
§01

Basic information

BASIC
Head office
6th Floor, Sumitomo Real Estate Nishishinjuku Building, 12-1 Honmachi 3-chome, Shibuya-ku, Tokyo 151-0071, Japan
Chief executive
Masamichi Koike
Capital
1,554,710,000  (15 100 million)
Employees (non-consolidated)
63 people
Employees (consolidated)
Start date
2005-02-08
End date
§02

Websites

1 DOMAINS
§03

Business

9
Drug discovery business for antibody therapeuticsDrug discovery support businessCommercialization of core technology (ADLib® System)Clinical development of candidate antibody CBA-1205 for cancer therapyOur proprietary antibody production technology and other technology platforms and servicesIDDDoppeLib™ADLib® SystemDrug discovery
§04

Related companies

13 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Biotecnol Limited
Supplier
JST
Supplier
ADC Therapeutics社
Alliance
Shanghai Henlius Biotech, Inc.
Alliance
国立研究開発法人理化学研究所
Alliance
KaioM BioScience Co., Ltd.
Japan Science and Technology Agency
Mizuho Bank, Ltd.
Bank
RIKEN
Saitama Small and Medium Enterprise Development Corporation
Sumitomo Mitsui Banking Corporation
Bank
Trans Chromosomics Co., Ltd.
Shareholder
株式会社イーベック
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

21 EVENTS

KaioM BioScience Co., Ltd. is a biotech venture founded in 2005. Since its establishment, it has been developing antibody-related technologies and engaging in drug discovery activities up to the present.Sources

Established KaioM BioScience Inc. (capital 10,000 thousand yen)Sources

Established KaioM BioScience Co., Ltd. (capital 10,000 thousand yen) in Bunkyo-ku, Tokyo, to commercialize the ADLib® system developed through joint research between the Genetic Dynamics Research Unit led by researcher Kunishi Ota of the National Institute of Advanced Industrial Science and Technology (currently our technical advisor) and the Saitama Prefecture Small and Medium Enterprise Promotion Corporation (currently the Saitama Prefecture Industrial Promotion Corporation).Sources

Entered into a joint research agreement with RIKEN to commercialize the ADLib® System and commenced research activitiesSources

Obtained exclusive implementation rights with sublicense to third parties for commercialization of the core technology (ADLib® System) from RIKEN and the Japan Science and Technology AgencySources

Relocated headquarters to Shinjuku-ku, TokyoSources

Signed a paid transfer agreement for patents related to the core technology (ADLib® System) with the Japan Science and Technology AgencySources

Listed shares on the Tokyo Stock Exchange MothersSources

Relocated main office to Shibuya-ku, TokyoSources

Acquired a majority of shares of Livetech Inc. and made it a subsidiarySources

Absorbed Livetech Inc. through a mergerSources

Invested in Ibeck Inc.Sources

Invested in Trans Chromosomics Inc.Sources

Entered into a licensing agreement with Swiss company ADC Therapeutics for the development of ADC LIV-1205.Sources

Signed a transfer agreement for the cancer therapeutic candidate antibody Tb535H (now CBA-1535) and the antibody modification technology Tribody™.Sources

Commenced Phase 1 clinical trials of our first clinical development product, the cancer therapeutic candidate antibody CBA-1205.Sources

Signed a licensing agreement with Shanghai Henlius Biotech (headquarters, Shanghai) for the development, manufacturing, and sales of cancer therapeutic antibodies LIV-2008 and LIV-2008b in the Greater China region (January 2023, license agreement terminated).Sources

Signed a licensing agreement with Shanghai Henlius Biotech (headquarters, Shanghai) for the development, manufacturing, and sales of cancer therapeutic antibodies LIV-2008 and LIV-2008b in the Greater China region.Sources

Transitioned from the Tokyo Stock Exchange Mothers market to the Growth market following a review of market classifications by the Tokyo Stock Exchange.Sources

Commenced the first worldwide clinical trial of Tribody™, the Phase 1 clinical trial of our clinical development product, the cancer therapeutic candidate antibody CBA-1535.Sources

Termination of this licensing agreement.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information6011101054960
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社カイオム・バイオサイエンス
Trade name (kana)
カイオムバイオサイエンス
Name in English
Corporation type
301
Address
〒151-0071 東京都渋谷区本町3丁目12番1号
Postal code
1510071
Prefecture code
13
City code
113
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2023-08-07
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2100376
METI gBizINFO6011101054960
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6011101054960
Trade name
株式会社カイオム・バイオサイエンス
Trade name (kana)
カイオムバイオサイエンス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都渋谷区本町3丁目12番1号
Postal code
1510071
Prefecture
東京都
Prefecture code
13
City or district
渋谷区
City code
113
Street address
本町3丁目12番1号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長 小池 正道
Capital
1085523000
Employees
49
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-08-07
Key information
6011101054960
§09

Sources & updates

SOURCES
↑